Trial Profile
A Randomized, 6-week Double-blind, Placebo-controlled, Flexible-dose, Parallel-group Study of Lurasidone Adjunctive to Lithium or Dovalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-response to Treatment With Lithium or Divalproex Alone.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Lurasidone (Primary)
- Indications Bipolar I disorders
- Focus Registrational; Therapeutic Use
- Acronyms PREVAIL-3
- Sponsors Sumitomo Pharma America
- 21 Oct 2014 Results of post-hoc analysis of lurasidone effects on 6-item MADRS subscale was presented at the 27th Annual Congress of the European College of Neuropsychopharmacology.
- 25 Jun 2013 Results presented at the 11th World Congress of Biological Psychiatry.
- 30 Aug 2012 New source identified and integrated (Clinical Trials Registry - India; CTRI2011-06-001808).